BCRX BioCryst Pharmaceuticals
- 7.030
- -0.420-5.64%
- 7.030
- 0.0000.00%
BioCryst Pharmaceuticals News
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst (BCRX) Receives a Buy From Bank of America Securities
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | BioCryst Pharmaceuticals, Inc. : Barclays Raises Target Price to $8 From $7
Earnings Call: BioCryst Pharmaceuticals Reports Strong Q3 Growth
12 Health Care Stocks Moving In Monday's Intraday Session
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript Summary
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
Express News | BioCryst Pharmaceuticals Shares Down 5.1% Premarket After Q3 Results
BioCryst Pharmaceuticals Sees Achieving Financial Milestones Without Raising Additional Funds >BCRX
Analysis
Price Target
No Data
No Data